ESMO Targeted Anticancer Therapies Congress 2025

The ESMO TAT Congress is dedicated to improving the conduct of early phase clinical trials in oncology by providing the latest scientific breakthroughs as well as workshops and educational reviews on pre-clinical and early clinical data.

Moreover, ESMO TAT 2025, as a unique multi-stakeholder Forum in the early drug development arena, will bring together investigators from academia, translational scientists, methodological experts and opinion leaders from industry, investor and regulatory bodies to highlight new data, promote collaboration and tackle challenges for accelerating the bench-to-bedside pathway to the benefit of our patients.
Learning objectives

In the Keynote lectures, Educational sessions, Special sessions with Industry, Workshops, Scientific sessions and Poster exhibition, attendees will be able to update their knowledge on:

    Innovation in phase I trials, including methods, design and endpoints
    Developments in preclinical modelling to support modern drug development
    Novel molecular imaging technologies
    Recent developments in cellular and gene-based therapies
    Early pipeline breakthroughs in novel kinase inhibitors, oral immunotherapies, next-generation macromolecules
    Methodological and regulatory challenges in the development of new agents
    Insights from the oncology early drug development and biotechnology industries